期刊文献+

多囊卵巢综合征患者血纤溶酶原激活抑制物-1水平的研究 被引量:2

The Ability of PAI-1 in Women with Polycystic Ovary Syndrome
暂未订购
导出
摘要 目的 探讨PCOS患者的血纤溶能力是否较正常对照者下降。方法 对照组2 0例、PCOS患者30例,分别取血检查组织纤溶酶原激活物(t- PA)、纤溶酶原激活抑制物(PAI -1)的活性,了解PCOS患者的血纤溶能力。结果 PCOS组的胰岛素(INS)、t- PA、PAI- 1分别为2 4±12mU/L、0 .17±0 .0 6KU/Ll、0 .88±0 .0 5AU/L。结论 PCOS患者的血纤溶能力较正常对照者有所下降。 Objective To evaluate the plasminogen activator system in women with polycystic ovary syndrome (PCOS). Methods Serum free-testosterone(F-T), insulin(INS), tissue plasminogen activator(t-PA), plasminogen activator inhibitor type-1(PAI-1) activity in thirty women with PCOS and in twenty controls were measured.Results The serum insulin was higher (mean±SD:24±12 mU/L),t-PA is lower (0.17±0.06 KU/L) and PAI-1 is higher (0.88±0.05 AU/L) in women with PCOS than that in the controls. Conclusion The plasminogen ability is lower in women with PCOS.
作者 邹琴燕 李红
出处 《苏州大学学报(医学版)》 CAS 北大核心 2005年第2期312-313,共2页 Suzhou University Journal of Medical Science
关键词 多囊卵巢综合征 血纤溶能力 纤溶酶原激活抑制物-1 polycystic ovary syndrome serum plasminogen ability plasminogen activator inhibitor type-1
  • 相关文献

参考文献6

  • 1曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129.
  • 2JakubowiczDJ,IuornoMJ,JakubowiczS, et al.Effects of metformin on early-pregnancy loss in the polycystic ovary syndrome[J].J Clin Endocrinol Metab, 2002,87(2):524-529.
  • 3William UA, Susie AB, John EC. The plasminogen activator system in women polycystic ovary syndrome[J].Fertil Steril,1998, 69(2):236-241.
  • 4Yildiz BO, Haznedaroglu IC, Kirazli S,et al. Global fibrionolytic capacity is decreased in polycystic ovary syndrome ,suggesting a prothrombotic state[J].J Clin Endocrinol Metab ,2002,87(8):3871-3875.
  • 5Schneie DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type 2 diabetic patients[J].Diabetes, 1993,42(1):1-7.
  • 6Morange PE, Alessi MC, Verdier M,et al. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level[J]. Arterioscler Thromb Vasc Biol,1999,19(5):1361-1365.

共引文献3228

同被引文献18

  • 1黄健康,李启富.胰岛素抵抗与多囊卵巢综合征[J].医学综述,2005,11(5):389-391. 被引量:8
  • 2唐平,李红辉,丁殊节,覃国珍,何涛,李家富.罗格列酮对2型糖尿病患者血浆tPA和PAI1活性的影响[J].实用医学杂志,2005,21(23):2690-2692. 被引量:1
  • 3Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor - 1 (PAI - 1 ) is not an independent risk factor in the polycystic ovary syndrome (PCOS) [J]. Clin Endocrinol ,2000,52:487.
  • 4William UA, Susie AB ,John EC. The plasminogen activator system in polycystic ovary syndrome [J]. Fertil Steril, 1998,69 ( 2 ) :236 - 241.
  • 5Yildiz Bo, Haznedaroglu IC, Kirazli S, et al. Global fibrionolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic stat[J]. J Clin Endocrinoc Metab ,2002,67 (8) :3871.
  • 6Orio F JT,Palomba S. Casulla T,et al. Is plasminogen activator inhibitor - 1 a cardiovascular risk factor in young women with polycystic ovary syndrome [ J ] ?. Reprd Biomed Online,2004 ,9:505 - 510.
  • 7李秀梅.岛素抵抗综合征[M].北京:人民卫生出版社,2001,59-180.
  • 8Schneie DJ, Nor dt TK, Sobel BE. Attenuated fibrinolysis and accelerated athenogenesis in type I diabetic patient [J]. Diabetes, 1993,42 (1):1.
  • 9Listenberger ll, Han X, Lewis SE, et al. Triglycerid. accumulation protects against fatty acid inducelipotoxicity [J]. PNAS, 2003, 100: 3077.
  • 10De Frène V,Vansteelandt S,T Sjoen G,et al.A retrospective study of the pregnancy,delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome[J].Human Reprod,2014,29(10):2333-2338.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部